Midatech Pharma Plc（纳斯达克股票代码：MTP）空头利率更新

Midatech Pharma plc (NASDAQ:MTP – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 38,700 shares, a growth of 26.9% from the December 15th total of 30,500 shares. Based on an average daily volume of 19,000 shares, the days-to-cover ratio is currently 2.0 days.

Institutional Trading of Midatech Pharma

A hedge fund recently bought a new stake in Midatech Pharma stock. Great Valley Advisor Group Inc. bought a new position in shares of Midatech Pharma plc (NASDAQ:MTP – Get Rating) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 49,600 shares of the company's stock, valued at approximately $27,000. Great Valley Advisor Group Inc. owned 0.25% of Midatech Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 4.21% of the company's stock.

Midatech Pharma Trading Up 5.3 %

Midatech Pharma stock traded up $0.04 during midday trading on Friday, reaching $0.70. The company's stock had a trading volume of 84,868 shares, compared to its average volume of 45,456. The stock's 50-day simple moving average is $1.14 and its 200-day simple moving average is $2.26. Midatech Pharma has a 52-week low of $0.63 and a 52-week high of $5.50.

About Midatech Pharma

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection.

Recommended Stories

• Get a free copy of the StockNews.com research report on Midatech Pharma (MTP)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.